Heron Therapeutics, Inc.
HRTX
$0.34
$0.000.69%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -3,557.25% | -297.44% | -48.71% | 51.45% | 98.07% |
| Total Depreciation and Amortization | -8.22% | -2.63% | -7.14% | -10.21% | -16.16% |
| Total Amortization of Deferred Charges | -22.67% | -19.96% | -14.98% | 10.80% | 110.38% |
| Total Other Non-Cash Items | 125.42% | 51.80% | 40.47% | 24.57% | -51.83% |
| Change in Net Operating Assets | 92.91% | 54.86% | -15.49% | -4,696.85% | -1,286.16% |
| Cash from Operations | 58.77% | 7.41% | -22.47% | -263.96% | -35.04% |
| Capital Expenditure | 61.83% | 67.00% | 81.42% | 27.54% | 17.50% |
| Sale of Property, Plant, and Equipment | -43.75% | -18.84% | 262.96% | 738.46% | 515.38% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -89.80% | -37.82% | -20.42% | 14,452.77% | 197.18% |
| Cash from Investing | -91.21% | -35.07% | -14.45% | 2,235.26% | 187.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,159.01% | 1,997.28% | 2,122.34% | 2,868.38% | -94.66% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -37.80% | -- | -- | -328,950.00% | -1,922.22% |
| Cash from Financing | 961.86% | 1,341.29% | 1,434.79% | 1,943.44% | -97.65% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 324.87% | 679.85% | 198.96% | 290.03% | -137.98% |